Quadriceps myostatin expression in COPD.

REFERENCES 1 Harari S, Caminati A. Pulmonary Langerhans’ cell histiocytosis. Eur Respir Mon 2009; 46: 155–175. 2 Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 739–748. 3 Bakker JA, Bierau J, Drent M. Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?Eur Respir J 2007; 30: 821–822. 4 Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23: 523–532. 5 Bierau J, Bakker JA, Lindhout M, et al. Determination of ITPase activity in erythrocyte lysates obtained for determination of TPMT activity. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1129–1132. 6 Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111: 360–367. 7 Vanderheiden BS. Human erythrocyte ‘‘ITPase’’: an ITP pyrophosphohydrolase. Biochim Biophys Acta 1970; 215: 555–558. 8 Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8: 1221–1228. 9 Lin S, McLennan AG, Ying K, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the ITPA gene. J Biol Chem 2001; 276: 18695–18701. 10 Arenas M, Duley J, Sumi S, et al. The ITPA c.94C.A and g.IVS2+21A.C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta 2007; 1772: 96–102.